Article

Odyssey Medical unveils punctal plug, occluder results

Odyssey Medical has introduced a punctal plug (Micro Flow) that is designed to provide a reversible means of partial occlusion by limiting the drainage of tears into the lacrimal duct.

Memphis, TN

-Odyssey Medical has introduced a punctal plug (Micro Flow) that is designed to provide a reversible means of partial occlusion by limiting the drainage of tears into the lacrimal duct. The device is intended for use in patients who have epiphora caused by a punctal stenosis or in instances where total punctal occlusion is considered too aggressive an approach.

In three sizes (small, medium, and large), the plug is available in sterile pre-loaded packaging that includes one pair of occluders and in non-sterile bulk packaging that includes five pairs.

In other news, the company announced results of a study showing a 92% retention rate for another occluder (Parasol). When Craig McCabe, MD, PhD, examined 108 patients who received the plug after artificial tears had failed to address their dry eye, 91% of them reported that their eyes had more moisture, and 77% reported fewer dry eye symptoms. Snellen acuity improved by one or more lines in 43% of the eyes, according to the company.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.